Page 30 - Early Access Program News Today

Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after...

Company receives IRB approval of study protocol Ampligen (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Tesla's FSD Beta software is rapidly progressing towards becoming a level 5 fully self-driving software. However, as the AI's capabilities grow, so has scrutiny by regulatory agencies. And today, an 8-month-old message sent by the NHTSA to Tesla asking to be included in the FSD Beta program has surfaced. After a long wait, Musk has finally agreed to turn on FSD Beta on the regulatory agency's in-house test Tesla vehicle.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

- Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Zeno represents a potential new standard of care for NRG1+ cancer -

/PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis, today announced the initial availability of the industrys first...

Mission Bio Launches Early Access Program for Single-Cell Measurable Residual Disease Detection in Blood Cancers - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced today the launch of their Premier...

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and...